Targets › ALDH5A1
5 programs from 5 companies in 8 trials: 4 Phase 2, 3 Phase 1, 1 Phase 4; Oncology, Neurology, Immunology; next expected readout Dec 2026.
Catalyzes one step in the degradation of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). (UniProt, P51649)
Open in Phaseline: the race on ALDH5A1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| The First Affiliated Hospital of University of South China | Valproate Sodium Succinate semialdehyde dehydrogenase inhibitor | ALDH5A1 | Phase 4 | Epilepsy | – |
| National Cancer Institute, Naples | Valproic Acid Succinate semialdehyde dehydrogenase inhibitor | ALDH5A1 | Phase 2 | Colorectal Cancer Metastatic; Adenocarcinoma of the Pancreas | Dec 2026 |
| Australasian Gastro-Intestinal Trials Group | Valproate Sodium Succinate semialdehyde dehydrogenase inhibitor | ALDH5A1 | Phase 2 | Metastatic Colorectal Cancer | Jun 2027 |
| Tanta University | Valproate Sodium Succinate semialdehyde dehydrogenase inhibitor | ALDH5A1 | Phase 2 | Temporomandibular Joint Internal Derangement (ADWR) | – |
| Erasmus Medical Center | Valproic Acid Succinate semialdehyde dehydrogenase inhibitor | ALDH5A1 | Phase 1 | Melanoma | Oct 2027 |
Melanoma (3) Metastatic Colorectal Cancer (1) Epilepsy (1) Colorectal Cancer Metastatic (1) Adenocarcinoma of the Pancreas (1) Temporomandibular Joint Internal Derangement (ADWR) (1)
mixed (2), small molecule (2), other (1)
Australasian Gastro-Intestinal Trials Group (1) The First Affiliated Hospital of University of South China (1) Erasmus Medical Center (1) National Cancer Institute, Naples (1) Tanta University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.